DAVID PAYNE
Board of Directors member
David Payne is Vice President and Head of Infectious Diseases Research for GSK where he leads a team focused on novel approaches to cure hepatitis B (HBV), viral and bacterial infections along with supporting GSKs portfolio of late-stage medicines for HBV, bacterial and fungal infections.
David has progressed multiple projects into clinical studies including a first in a new class of antibiotics in Phase 3 trials, and establishing a portfolio of therapeutics to cure HBV. Furthermore, he led the creation of the GSK:Vir alliance during the SARS-CoV2 pandemic.
Previous roles for David include Head of Medicine Opportunities where he was responsible a portfolio of high value medicines in ID, COPD, Duchenne Muscular Dystrophy & eye diseases and from 2017-19 he was Site Leader of GSKs US R&D hub (Upper Providence, Collegeville, PA).
David has been an advisor to multiple government and non-government agencies on approaches to address AMR, including contributions to President Obama’s report on AMR. He was the first to integrate public private partnerships as a solution to tackle AMR and is currently the Principle Investigator of GSK’s BARDA (US HHS) contract providing >$200M for sharing the risk/cost of progressing our antibiotic portfolio.
David is currently a board member of Life Sciences of PA & GSK’s US Charity Contributions Committee. He has a PhD and DSc from The Medical School, University of Edinburgh, UK.
YOU MAY ALSO BE INTERESTED IN
Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.
Discover more about who we are, the work we do and what we're doing to advance HIV science, support the delivery of HIV treatment and care; and work with partners to address the stigma and discrimination faced by people living with HIV.
NP-GBL-HVX-COCO-220025 November 2024
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
